ELI LILLY & Co
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Zyprexa (olanzapine) by Year
Zyprexa (olanzapine) — Worldwide revenue ($M) [legacy separate disclosure] ($M)
Eli Lilly Zyprexa (olanzapine): $116M in FY2024, down 93.1% from a year earlier. That is the lowest of the 9 years on record here. No newer figure appears in the documents we track.
Where the FY2024 figure comes from
“|| Zyprexa (4) | 2.0 | 114.3 | 116.3 | 1,694.8 | (93)”
Source: Form 10-K FY2024 (filed 2025-02-19) ↗
Reported in Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zyprexa (olanzapine) — Worldwide revenue ($M) [legacy separate disclosure] ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 116 | -93.1% | Form 10-K FY2024 (filed 2025-02-19) ↗ |
| FY2023 | Dec 31, 2023 | 1,695 | +403.1% | Form 10-K FY2023 (filed 2024-02-21) ↗ |
| FY2022 | Dec 31, 2022 | 337 | -21.7% | Form 10-K FY2022 (filed 2023-02-22) ↗ |
| FY2021 | Dec 31, 2021 | 430 | +5.9% | Form 10-K FY2021 (filed 2022-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 407 | -13.7% | Form 10-K FY2020 (filed 2021-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 471 | -18.9% | Form 10-K FY2019 (filed 2020-02-19) ↗ |
| FY2018 | Dec 31, 2018 | 581 | 0.0% | Form 10-K FY2018 (filed 2019-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 581 | -19.9% | Form 10-K (filed 2018-02-20) ↗ |
| FY2016 | Dec 31, 2016 | 725 | – | Form 10-K (filed 2018-02-20) ↗ |
Breakdown
What makes up zyprexa (olanzapine)
Cite this data
StockData. (2026). Eli Lilly Zyprexa (olanzapine) ($M), annual FY2016–FY2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-zyprexa-ww
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.